Pharmacology of bisphosphonates

被引：152

作者：

Cremers, Serge ^{[1
,2
]}

Drake, Matthew T. ^{[3
,4
]}

Ebetino, F. Hal ^{[5
,6
]}

Bilezikian, John P. ^{[2
]}

Russell, R. Graham G. ^{[6
,7
]}

机构：

[1] Columbia Univ, Irving Med Ctr, Vagelos Coll Phys & Surg, Div Lab Med,Dept Pathol & Cell Biol, New York, NY 10032 USA

[2] Columbia Univ, Irving Med Ctr, Vagelos Coll Phys & Surg, Div Endocrinol,Dept Med, New York, NY USA

[3] Mayo Clin, Coll Med, Dept Endocrinol, Rochester, MN USA

[4] Mayo Clin, Coll Med, Kogod Ctr Aging, Rochester, MN USA

[5] Univ Rochester, Dept Chem, Rochester, NY USA

[6] Univ Sheffield, Sch Med, Mellanby Ctr Bone Res, Sheffield, S Yorkshire, England

[7] Univ Oxford, Inst Musculoskeletal Sci, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr,Nuffield Orthopaed Ctr, Oxford, England

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2019年 / 85卷 / 06期

关键词：

Bisphosphonates; bone; osteoporosis; pharmacology; NITROGEN-CONTAINING BISPHOSPHONATES; BONE-MINERAL DENSITY; DISEASE SYSTEMS-ANALYSIS; RISEDRONATE; 35; MG; ZOLEDRONIC ACID; IN-VITRO; BREAST-CANCER; BIOCHEMICAL MARKERS; PAGETS-DISEASE; DRUG HOLIDAY;

D O I：

10.1111/bcp.13867

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Four decades of preclinical and clinical research of the pharmacology of bisphosphonates have generated data and concepts that have considerably improved their clinical use. However, despite this progress several pharmacological aspects relevant to bisphosphonate action on bone are still incompletely understood. This is mainly due to the complex, unique pharmacological properties of bisphosphonates. We review here the pharmacokinetic and pharmacodynamic data of bisphosphonates that are relevant for their clinical application and for the potential choice of a given compound, focusing on uncertainties that still exist. This article is part of a Special Issue entitled Bisphosphonates. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：1052 / 1062

页数：11

共 113 条

[1] TREATMENT OF PAGETS-DISEASE OF BONE WITH INTRAVENOUS 4-AMINO-1-HYDROXYBUTYLIDENE-1,1-BISPHOSPHONATE
ADAMI, S
SALVAGNO, G
GUARRERA, G
MONTESANTI, F
GARAVELLI, S
ROSINI, S
LOCASCIO, V
[J]. CALCIFIED TISSUE INTERNATIONAL, 1986, 39 (04) : 226 - 229
[2] ALENDRONATE DISTRIBUTED ON BONE SURFACES INHIBITS OSTEOCLASTIC BONE-RESORPTION IN-VITRO AND IN EXPERIMENTAL HYPERCALCEMIA MODELS
AZUMA, Y
SATO, H
OUE, Y
OKABE, K
OHTA, T
TSUCHIMOTO, M
KIYOKI, M
[J]. BONE, 1995, 16 (02) : 235 - 245
[3] Bauer DC, 2009, J BONE MINER RES, V24, P2032, DOI [10.1359/JBMR.090526, 10.1359/jbmr.090526]
[4] Removal of clodronate by haemodialysis in end-stage renal disease patients
Beigel, AE
Rienhoff, E
Olbricht, CJ
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 (12) : 2266 - 2268
[5] Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability
Bellido, Teresita
Plotkin, Lilian I.
[J]. BONE, 2011, 49 (01) : 50 - 55
[6] Berenson JR, 2001, CANCER, V91, P144, DOI 10.1002/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO
[7] 2-Q
[8] Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function
Berenson, JR
Rosen, L
Vescio, R
Lau, HS
Woo, M
Sioufi, A
Kowalski, O
Knight, RD
Seaman, JJ
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (04) : 285 - 290
[9] American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
Berenson, JR
Hillner, BE
Kyle, RA
Anderson, K
Lipton, A
Yee, GC
Biermann, JS
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3719 - 3736
[10] Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study
Bergner, R
Dill, K
Boerner, D
Uppenkamp, M
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (07) : 1281 - 1285

← 1 2 3 4 5 6 7 8 9 10 →